日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Contributions and recognition of patient partners in pediatric health research: A rapid scoping review protocol

患者伙伴在儿科健康研究中的贡献和认可:快速范围界定审查方案

Pawliuk, Colleen; Niazi, Elaha; Hermansen, Anne-Mette; Barrans, Candice; Pietramala, Danielle; Zamma, Gabriel; Siden, Harold Hal

Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential

弥漫性大B细胞淋巴瘤中的非IG::MYC赋予了其不同的基因组构型和MYC转录激活潜能。

Zhang, Chunye; Stelloo, Ellen; Barrans, Sharon; Cucco, Francesco; Jiang, Dan; Tzioni, Maria-Myrsini; Chen, Zi; Li, Yan; Swennenhuis, Joost F; Makker, Jasmine; Rásó-Barnett, Lívia; Liu, Hongxiang; El-Daly, Hesham; Soilleux, Elizabeth; Shah, Nimish; Nagumantry, Sateesh Kumar; Kyaw, Maw; Prahladan, Mahesh Panatt; Tooze, Reuben; Westhead, David R; Feitsma, Harma; Davies, Andrew J; Burton, Catherine; Johnson, Peter W M; Du, Ming-Qing

Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up

REMoDL-B研究中,根据分子亚组分析,在弥漫性大B细胞淋巴瘤的R-CHOP方案中加入硼替佐米的疗效存在差异,随访时间为5年。

Davies, Andrew J; Barrans, Sharon; Stanton, Louise; Caddy, Josh; Wilding, Sam; Saunders, Geoff; Mamot, Christoph; Novak, Urban; McMillan, Andrew; Fields, Paul; Collins, Graham P; Stephens, Richard; Cucco, Francesco; Sha, Chulin; van Hoppe, Moniek; Tooze, Reuben; Davies, John R; Griffiths, Gareth; Schuh, Anna; Burton, Catherine; Westhead, David R; Du, Ming-Qing; Johnson, Peter W M

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma

纵向表达谱分析可识别出ABC型弥漫性大B细胞淋巴瘤患者中的高危亚群

Bewicke-Copley, Findlay; Korfi, Koorosh; Araf, Shamzah; Hodkinson, Brendan; Kumar, Emil; Cummin, Thomas; Ashton-Key, Margaret; Barrans, Sharon; van Hoppe, Suzan; Burton, Cathy; Elshiekh, Mohamed; Rule, Simon; Crosbie, Nicola; Clear, Andrew; Calaminici, Maria; Runge, Hendrik; Hills, Robert K; Scott, David W; Rimsza, Lisa M; Menon, Geetha; Sha, Chulin; Davies, John R; Nagano, Ai; Davies, Andrew; Painter, Daniel; Smith, Alexandra; Gribben, John; Naresh, Kikkeri N; Westhead, David R; Okosun, Jessica; Steele, Andrew; Hodson, Daniel J; Balasubramanian, Sriram; Johnson, Peter; Wang, Jun; Fitzgibbon, Jude

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

DDX3X 缺失是弥漫性大 B 细胞淋巴瘤的不良预后标志物,并且与侵袭性非霍奇金淋巴瘤亚型的化疗耐药性相关。

Kizhakeyil, Atish; Zaini, Nurmahirah Binte Mohammed; Poh, Zhi Sheng; Wong, Brandon Han Siang; Loh, Xinpeng; Ng, Aik Seng; Low, Zun Siong; Prasannan, Praseetha; Gong, Chun; Tan, Michelle Guet Khim; Nagarajan, Chandramouli; Huang, Dachuan; Lu, Pang Wan; Lim, Jing Quan; Barrans, Sharon; Ong, Choon Kiat; Lim, Soon Thye; Chng, Wee Joo; Follows, George; Hodson, Daniel J; Du, Ming Qing; Goh, Yeow Tee; Tan, Suat Hoon; Grigoropoulos, Nicholas Francis; Verma, Navin Kumar

Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial

一线 R-CODOX-M/R-IVAC 化疗治疗高危弥漫性大 B 细胞淋巴瘤(IPI 3-5)可取得良好疗效:一项英国 NCRI II 期试验的结果

McMillan, A K; Phillips, E H; Kirkwood, A A; Barrans, S; Burton, C; Rule, S; Patmore, R; Pettengell, R; Ardeshna, K M; Lawrie, A; Montoto, S; Paneesha, S; Clifton-Hadley, L; Linch, D C

Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit

独特的基因改变揭示了伴有MYC/BCL2双重打击的弥漫性大B细胞淋巴瘤的进化历史和异质性分子分级

Cucco, Francesco; Barrans, Sharon; Sha, Chulin; Clipson, Alexandra; Crouch, Simon; Dobson, Rachel; Chen, Zi; Thompson, Joe Sneath; Care, Matthew A; Cummin, Thomas; Caddy, Josh; Liu, Hongxiang; Robinson, Anne; Schuh, Anna; Fitzgibbon, Jude; Painter, Daniel; Smith, Alexandra; Roman, Eve; Tooze, Reuben; Burton, Catherine; Davies, Andrew J; Westhead, David R; Johnson, Peter W M; Du, Ming-Qing

Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial

利妥昔单抗联合CODOX-M/IVAC方案治疗高危伯基特淋巴瘤患者(IPI 3-5)取得良好疗效:一项英国国家癌症研究所(NCRI)II期试验的结果

Phillips, Elizabeth H; Burton, Catherine; Kirkwood, Amy A; Barrans, Sharon; Lawrie, Anthony; Rule, Simon; Patmore, Russell; Pettengell, Ruth; Ardeshna, Kirit M; Montoto, Silvia; Paneesha, Shankara; Clifton-Hadley, Laura; Linch, David C; McMillan, Andrew K

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial

ACCEPT 研究——阿卡替尼联合利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松龙(R-CHOP)治疗弥漫性大B细胞淋巴瘤(DLBCL):一项Ib/II期开放标签非随机临床试验的研究方案

Davies, Andrew; Barrans, Sharon; Burton, Cathy; Mercer, Katy; Caddy, Joshua; Chinnery, Fay; Day, Laura; Fernando, Diana; Ardeshna, Kirit; Collins, Graham; Radford, John; Rule, Simon; McMillan, Andrew; Johnson, Peter; Griffiths, Gareth

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

分子高级别B细胞淋巴瘤:定义一个需要不同治疗方法的预后不良群体

Sha, Chulin; Barrans, Sharon; Cucco, Francesco; Bentley, Michael A; Care, Matthew A; Cummin, Thomas; Kennedy, Hannah; Thompson, Joe S; Uddin, Rahman; Worrillow, Lisa; Chalkley, Rebecca; van Hoppe, Moniek; Ahmed, Sophia; Maishman, Tom; Caddy, Josh; Schuh, Anna; Mamot, Christoph; Burton, Catherine; Tooze, Reuben; Davies, Andrew; Du, Ming-Qing; Johnson, Peter W M; Westhead, David R